US 12,318,399 B2
Stabilized compositions comprising cannabidiol
Alexandra M. Capano, Philadelphia, PA (US); and Pradeep Singh Tanwar, Fletcher (AU)
Assigned to Ecofibre USA Inc., Georgetown, KY (US); and The University of Newcastle, Callaghan (AU)
Filed by Ecofibre USA Inc., Georgetown, KY (US); and The University of Newcastle, Callaghan (AU)
Filed on May 6, 2024, as Appl. No. 18/655,974.
Application 18/655,974 is a division of application No. 18/493,997, filed on Oct. 25, 2023, granted, now 12,011,451.
Claims priority of provisional application 63/381,038, filed on Oct. 26, 2022.
Prior Publication US 2024/0293433 A1, Sep. 5, 2024
Int. Cl. A61K 36/00 (2006.01); A61K 31/00 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/353 (2006.01); A61K 31/704 (2006.01); A61K 36/185 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/658 (2023.05) [A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/353 (2013.01); A61K 31/704 (2013.01); A61K 36/185 (2013.01); A61P 35/00 (2018.01)] 4 Claims
 
1. A method of treatment of a gynecological disease or disorder comprising administering to a patient in need thereof an effective amount of a composition comprising:
a cannabis extract and a flavonoid selected from the group consisting of: a flavonoid having the following structure:

OG Complex Work Unit Chemistry
wherein attached at each of R3, R5, R6, R7, R8, R2′, R3′, R4′, R5′, and R6′ is a hydrogen or a hydroxyl;
wherein the cannabis extract is selected from the group consisting of: a broad spectrum hemp extract, a full spectrum hemp extract, a cannabidiol (CBD) isolated, and combinations thereof;
wherein the cannabis extract comprises between 50% and 100% by weight of cannabidiol; and
wherein the ratio of the cannabis extract to the flavonoid is between 5 μg/mL: 1 μM to 5 μg/mL: 200 μM.